

INNOVATION

IN REMOTE MEDICAL MONITORING

Biotricity is a medical technology company committed to improving healthcare by developing solutions that aid chronic disease prevention and management. Biotricity's premier product is "Bioflux", an ECG monitoring system that will be prescribed by physicians to diagnose and remotely monitor cardiac patients.

Biotricity's R&D continues to focus on the preventative healthcare market, with the vision of putting health management into the hands of the individual. The company's team has a longstanding history in launching successful products and aims to support the self-management of critical and chronic conditions with the use of innovative mobile solutions, to ease the growing burden on the healthcare system.

BIOFLUX

THE COMPLETE SOLUTION

FOR REAL-TIME REMOTE CARDIAC MONITORING

Bioflux is the Company's advanced Mobile Cardiac Telemetry (MCT) system consisting of a high-precision ECG device and the Company's proprietary software. It provides real-time remote data, monitored 24/7, for up to 30 consecutive days. The technology also has numerous additional applications beyond remote cardiac monitoring and is insurance reimbursable.

BIOLIFE

THE PERSONAL WEARABLE HEART MONITOR WITH CLINICAL ACCURACY FOR SELF-MANAGED PREVENTIVE CARE


Biolife is a personal heart monitor for consumer use, meant for patients at risk for, or diagnosed with cardiovascular disease. Unlike widely available lifestyle solutions and fitness trackers, Biolife is a medical grade solution that is clinically accurate. It provides information on your heart's performance of the same quality as your doctor uses. With medical-grade precision, Biolife will also give you precise information on your respiration, physical activity, calorie burn, core body temperature, and more. Utilizing a modern design user interface and when used in a manner consistent with your doctor's instructions, Biolife will guide your efforts to manage your heart condition and improve the quality of your life.

"Are medical grade devices the next generation of wearables?"

- FORBES

"Innovative mobile solutions to ease the growing burden on the healthcare system"

- Waqaas Al-Siddiq
Chairman & CEO
biotricity



In This Report

- Technology
- Strategy
- The Market
- Industry Sectors
- Capitalization
- Investment Opinion

PROPRIETARY TECHNOLOGY

Real-time remote biometric monitoring and diagnostic solutions for the medical consumer market
Designed to leverage insurance reimbursement

RESEARCH

Current projects funded by the NRCC
Predictive value for preventive healthcare applications.
Research study grant for next generation

SUPERIOR MODEL

Mobile Cardiac Telemetry MCT
Technologically superior and financially attractive model for medical Practitioners

PARTNERSHIPS

Partnerships with Canada NRC CNRC,
Alberta Health Services and the University of Calgary
BTYC retains ownership of all intellectual property rights

**THE TOTAL CONNECTED HEALTH MARKET IS
EXPECTED TO GROW AT A 33% CAGR**

COMPETTITIVE ADVANTAGES OF BIOTRICITY'S MCT SOLUTIONS

- Recurring business model
- Superior and more user-friendly diagnostics
- Recurring reimbursement to doctors, hospitals and IDTFs
- Compliance of BTCY technology with Insurance Billing Codes
- Global Cellular connectivity enables emergency response and international applications
- Motion recognition tracks exercise and activity - detects disorientation
- Technology easily adaptable to adjacent target markets and applications
- Increasing acceptance of advanced and user-friendly BTCY medical monitoring technology and software by physicians and consumers
- Monitoring from the comfort of your home or work
- Easy patient compliances with care-giver's instructions
- Avoidance of unnecessary hospital visits
- Increase patient compliance and cooperation

CONNECTED HEALTH MARKET

Connected Health Market

Growth at 33% CAGR by 2020



CAPITALIZATION

Symbol	BTCY
Exchange	OTC QB
Current Price	\$2.45
52 Week Range	\$1.53 - \$2.98
Average Volume	4,000
Shares Authorized	100,000,000
Shares Outstanding	25.6
Float	4.5 Mill
Market Cap	63 Million

THE MARKET

Estimated at \$59 Billion

The total connected health market is expected to grow at a 33% CAGR, reaching \$59 Billion by 2020.

Market growth has been driven by increasing high-quality offerings of smart gadgets and the wide-spread utilization of connected medical devices and mHealth apps, such as Biotricity's Bioflux and Biolife in the management of chronic diseases.

Rising healthcare costs are creating a need for medical grade and more affordable monitoring, diagnosis and treatment options. The wide availability of robust cellular and WIFI networks at reasonable cost, capable of providing uninterrupted healthcare diagnosis and monitoring services, support the fast expansion of the market.

The easy access to this technology and the focus on patient-centric healthcare are expected to drive the expansion of the market during the next few years. Growth beyond these expectations is currently only held back by the fear of data theft and the existing resistance of physicians to apply the new technology and educate their patients in the use of these new devices and software.

Once these applications will be made available more widely for iOS and Android, the market is bound to expand even more rapidly.

173 MILLION UNITS

According to the International Data Corporation, wearable device shipments will reach 173 million units by 2019. At the same time, cardiovascular disease related cost will reach \$1.1 Trillion by 2030.




Medical Care is Changing

The face of medical care is rapidly changing. In order to maintain profitability, cost needs to be managed carefully, as opposed to the insurance-driven cost pass-through model of the past. Healthcare providers who do not optimally manage cost, and are not able to reduce costly patient hospital visits, are being penalized.

Remote Patient Monitoring Solutions

The current economical environment and the pressure on the entire medical system to reduce cost, forces hospitals to transform "volume to value." Medicare's commitment to risk-based arrangements means that 85% of all hospital payments are expected to be value-based by the end of 2016. Innovations in mobility, wearable tech medical devices providing vital and medical-grade biometric monitoring, such as Biotricity's products, are at the heart of the next generation of patient care.



Medical Grade Data

In order to make this new technology successful, companies have to deliver medical grade data that is scientifically accurate and reliable, coupled with a technology that provides an optimal user experience. BTCY's remote patient monitoring solutions deliver this promise. It supports those efforts by helping to monitor chronically ill patients at home or at work and intervene earlier, reducing the likelihood of hospital admissions. BTCY's products significantly improve care delivery, provide a personalized patient approach and create favorable financial results for physicians, hospitals and patients.

Benefits of Biometric Remote Monitoring

The benefits of remote care are plentiful and biometric remote monitoring is happening right now and it's working wonders. **biotricity's** product offerings provide the tools to improve real time monitoring of patient conditions, personalize and improve physician/patient relationships and drastically reduce cost.

- Decreases resource requirements
- Generates significant savings per patient
- Improves care coordination
- Produces increased ROI for physicians and hospitals
- Increases patient compliance

Biotricity is expanding into Consumer Health for Chronic Care

The number of people diagnosed with chronic illnesses is increasing exponentially and clinically reliable mobile monitoring devices can provide a cost effective solution for disease management. Based on the rapidly increasing expansion of mobile networks for consumers, biotricity is expanding medical-grade monitoring into the consumer market via its biolife solution. This product empowers users to self-manage chronic conditions and helps users to make lifestyle changes by combining medically relevant ECG data with social media interactivity and a lifestyle log.



Management

Waqas Al-Siddiq, Chairman, CEO & Founder is an expert in wireless communication technology. Academically, he was distinguished for his various innovative designs in digital, analog, embedded and micro-electro-mechanical products. His work was published in conferences such as IEEE and the National Communication Council. Waqaas has held several high-level design positions in IBM, AMD and Intel. Waqaas has a dual Bachelor's degree in Computer Engineering and Economics, a Master's in Computer Engineering from Rochester Institute of Technology and a Master's in Business Administration from the Henley Business School. He is completing his Doctorate in Business Administration at Henley, with a focus on Transformative Innovations in Billion Dollar Markets.

Amir Ali, Chief Development Officer - Mr. Ali has over 20 years of experience in launching companies and producing innovative products, services and solutions. Prior to joining biotricity, Mr. Ali served as CEO at AT Labs Inc., where his team pioneered the concept of wireless mobile thin clients to access secure enterprise applications through the cloud for customers in healthcare, government, enterprise and the retail sector. Under his guidance, companies have grown in revenue from zero to over \$160 million. He has worked with many leading industrial and financial institutional funders, including Jafo, Bay Partners and JP Morgan, with whom he has raised over \$35 million.

Spencer LaDow, Vice President—Engineering - Spencer is an expert in wireless communication and has worked with the United States Department of Defense. His academic career was highlighted by various innovative projects and designs. Spencer obtained his undergraduate degree while balancing a full time job at Flightline Systems Ultra Electronics, a small defense contractor. His specialties are in the design and implementation of radio frequency, digital, analog, embedded software and PC software. Spencer also has experience in working with marketing, sales, and manufacturing teams in order to develop products for large-scale output. Spencer has a Bachelor's degree in Computer engineering from Rochester Institute of Technology.

Board of Directors

Waqas Al-Siddiq, Chairman, CEO & Founder

Norman Betts, PhD - Accomplished professor and accountant, also serves as a board member for the Bank for Canada. Mr. Betts was a member of the New Brunswick Legislative Assembly and held three different cabinet positions, including Minister of Finance.

Dave Rosa - Dave was CEO of Sunshine Heart, served as President and Chief Executive Officer and took the company public, raising \$120 Million during his tenure. Mr. Rosa was Vice President of Global Marketing for Cardiac Surgery at St. Jude Medical, Inc. Mr. Rosa also held top management positions at A-Med Systems Inc. and at SCIMED Life Systems.

Board of Advisors

John Rother - Medicare Policy Expert, President and CEO for the National Coalition of Healthcare. Worked for AARP for 27 years and was Chief Counsel for Labor and Health for U.S. Senator Jacob Javist. Mr. Roth received the Robert Ball Award for Outstanding Achievements in Social Insurance and Medicare from the Academy of Social Insurance.

Dr. Danny Sands - Participatory medicine pioneer. Dr. Sands spent six years at Cisco as Chief Medical Informatics officer. Prior he was chief medial officer for Zix Corporation. He holds degrees form Brown University, Ohio State University and the Harvard School for Public Health. He is the recipient of numerous health IT awards and has been elected to fellowship in both the American College of Physicians and the American College of Medical Informatics. Dr. Sands is a founder and co-chair of the Society for Participatory Medicine and he was recognized by Health Leaders Magazine as one of "20 People Who Make Healthcare Better"

SeeThruEquity Initiates Coverage on Biotricity, Inc. (OTCQB: BTCY) with a Price Target of \$4.20

November 18, 2016

Partnership Expands Digital Health Coaching, Patient Engagement

November 18, 2016

The proven health trackers saving thousands of lives

November 16, 2016

Biotricity (BTCY) About to Be Put to a Test It Wants to Take

November 15, 2016

Biotricity and Global to Local to Develop Chronic Care Solutions to Address Current Gaps in the Market

November 15, 2016

CEO of Biotricity Discusses Medical Wearable Benefits

November 8, 2016

Biotricity (BTCY) Start Where Apple (AAPL) and Fitbit (FIT) Stop

November 7 , 2016

Renowned Cardiologist Dr. Rony Shimony Joins Biotricity Board of Advisors

November 7, 2016

Biotricity Receives 501k clearance from the Food & Drug Administration


November 7, 2016

Biotricity Receives 501k clearance from the Food & Drug Administration

October 24, 2016

Biotricity Receives a FDA 510(k) Clearance – Marks Major Milestone in Path to Commercialization

October 18, 2016



SWI Investment Opinion

StockWatchIndex has been following biotricity since the initialization of coverage by SWI in July of 2016 and has met with management several times. Not only does the CEO have significant experience in the wearable medical device sector, but has also established a high caliber team of engineers, managers and a stellar advisory board to advance the company. BTCY has entered into crucial partnerships with large corporations in the communication and medical sector and is in the process of expanding its business development and sales team with vast experience in the MCT and cardiac monitoring market.

BTCY has received clearance for a Class II medical product for its proprietary ECG software and is preparing FDA filing for the BTCY hardware. To support these efforts, BTCY has successfully executed an oversubscribed bridge funding during the summer of 2016.

The Bioflux MCT device is expected to be deployed into hospitals, clinics, physicians' offices and IDTFs, on a pay-per-use basis. The MCT diagnostic read currently is a reimbursable service from payers such as Medicare and other insurance companies. In the United States, billing codes for an MCT diagnostic read are currently available under the American Medical Association Current Procedural Terminal, with a current average reimbursement rate of \$850 per read (a read is between 1 and 30 days long, with typical durations being 7 to 10 days).

We believe that Biotricity is well on its way to achieve its stated goals. The company has made significant process in R&D, established appropriate manufacturing relationships and implemented corporate structures that should generate the projected financial results, beginning with revenue generation during the first half of 2017. As it is the case often times with medical or biotech startups, achieving these goals is subject to the timely availability of required expansion capital. Subject to these limitations, we reiterate our "Buy Ratings Opinion". 2017 will be a milestone year in the development for the Company.

Investment Highlights

- The limited number of competitors makes this an attractive market for new entrants
- ECG reporting software, and introduction and access to a third-party 24/7 ECG monitoring center.
- Bioflux's pay-per-use strategy, with no fee for device purchases
- Free to doctors and revenue is expected to be derived from insurance reimbursable ECG reads.
- Fees paid to BTCY as a technology vendor and to the monitoring center for their services.
- Provides recurring reimbursements to doctors, hospitals and IDTFs
- Provides a revenue model that fits within the established insurance billing practices
- Provide built-in cellular connectivity, enabling immediate alert to user in the event of an emergency
- Provides motion tracking to detect exercise, activity, and disorientation
- Incorporates technology that is future-ready; form and function enables opportunities adjacent to the MCT market.
- Introduce medical-grade monitoring into the consumer market via proposed Biolife solution,
- Optimized user experience that combines ECG data and social media interactivity with a lifestyle log



StockWatchIndex, LLC

SWI Research

Rainer Poertner, Chief Analyst
4712 Admiralty Way, #173
Marina del Rey, CA 90292
310.614.2454
info@stockwatchindex.com
www.stockwatchindex.com



Waqas Al-Siddiq

Chairman, CEO & Founder
275 Shoreline Drive, Suite 150
Redwood City CA 94065
1.800.590.4155
www.biotricity.com
investors@biotricity.com

DISCLOSURE - This report has been prepared and distributed by StockWatchIndex, LLC (SWI). SWI is not a licensed broker-dealer or a licensed investment advisor and does not generate any investment banking or commission-based revenue with respect to the securities of the company described herein. StockWatchIndex is a Research and Information Marketing firm that has been engaged by biotricity to increase market awareness for biotricity and has been compensated for the preparation of this report with stock warrants at the fair market value of BTCY. The statements in this report are based on information from the company and/or other third party/public sources that we consider reliable, but we do not guarantee to be accurate or complete and nothing in this report may be construed as investment advice. Statements included in this report may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand and the company's ability to maintain sufficient working capital to timely execute its business plan and meet its financial projections. All information contained herein is subject to change without notice. SWI has no obligation to correct any errors and cannot be held liable for any third party public sources information herein, including information from the company. This is not an offer to buy or sell, or the solicitation of an offer to buy or sell any securities in the company, or any other stock mentioned in this report, in any jurisdiction where such an offer or solicitation would be illegal. © Copyright 2017 StockWatchIndex, LLC.